EVD-004

EVD-004 is an experimental engineered cytokine being developed by Evozyne for the treatment of autoimmune diseases. It is part of a broader portfolio of engineered protein candidates created using Evozyne's proprietary platform, which aims to optimize protein function for therapeutic use. The mechanism of action for EVD-004 involves a biased signaling approach, where the cytokine is engineered to separate beneficial anti-inflammatory signaling from unwanted pro-inflammatory effects. This selective modulation is intended to provide a more targeted and safer treatment option for various immune-mediated disorders. As of early 2024, the program is in the discovery stage of development.